Iovance Biotherapeutics, Inc.
IOVA
Pozycja w akcjach
#2785
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Cena akcji
$14.87
Kapitalizacja rynkowa
$6.74B
Zmiana (1 dzień)
4.64%
Zmiana (1 rok)
540.91%
Kraj
US
Handel Iovance Biotherapeutics, Inc. (IOVA)
Kategoria
Healthcare
Wskaźnik P/B dla Iovance Biotherapeutics, Inc. (IOVA)
Wskaźnik P/B na dzień October 2026 TTM: 8.69
Według najnowszych raportów finansowych i ceny akcji Iovance Biotherapeutics, Inc., obecny wskaźnik P/B (TTM) wynosi 8.69. Na koniec 2023 wynosił 3.27.
Historia wskaźnika P/B dla Iovance Biotherapeutics, Inc. od 2008 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 8.69 | 187.79% |
| 2024 | 3.02 | -7.66% |
| 2023 | 3.27 | 60.54% |
| 2022 | 2.04 | -56.76% |
| 2021 | 4.71 | -51.81% |
| 2020 | 9.77 | -15.09% |
| 2019 | 11.51 | 523.36% |
| 2018 | 1.85 | -48.53% |
| 2017 | 3.59 | 55.91% |
| 2016 | 2.30 | -30.18% |
| 2015 | 3.30 | -24.84% |
| 2014 | 4.38 | -24.70% |
| 2013 | 5.82 | -475.21% |
| 2012 | -1.55 | -73.87% |
| 2011 | -5.94 | -104.65% |
| 2010 | 127.82 | -101.69% |
| 2009 | -7.55K | -112.90% |
| 2008 | 58.49K | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 6.251 | -28.08% |
US
|
|
| 13.2547 | 52.51% |
US
|
|
| 4.208 | -51.58% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -28.87% |
NL
|
